Nuvation Bio's Ibtrozi Gets Japan Approval for Advanced ROS1-positive Non-Small Cell Lung Cancer

MT Newswires Live

Sep 19

Nuvation Bio (NUVB) said Friday that Japan's Ministry of Health, Labour and Welfare has approved its Ibtrozi therapy to treat adult patients with advanced ROS1-positive non-small cell lung cancer.

The company said that Nippon Kayaku will market Ibtrozi in Japan as part of a previously signed agreement in 2023.

The approval from Japan was based on data from a phase 2 clinical study researching Ibtrozi in patients globally, including Japan, the company said.

The company said that when the reimbursement price in Japan is set, which is expected in Q4, it will receive a $25 million milestone payment to advance its pipeline and portfolio.

Nuvation Bio added that Japan's Ministry of Health, Labour and Welfare has also approved AmoyDx PLC Panel as a companion diagnostic to identify patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who may benefit from treatment with Ibtrozi.

Shares of the company were up 2.1% in recent Friday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2568683442"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568683442\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568683442?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-19 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568683442","market":"us","top_or_hot":-1,"title":"Nuvation Bio's Ibtrozi Gets Japan Approval for Advanced ROS1-positive Non-Small Cell Lung Cancer","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a> (NUVB) said Friday that Japan's Ministry of Health, Labour and Welfare has approved its Ibtrozi therapy to treat adult patients with advanced ROS1-positive non-small cell lung cancer.</p><p>The company said that <a href=\"https://laohu8.com/S/NPKYF\">Nippon Kayaku</a> will market Ibtrozi in Japan as part of a previously signed agreement in 2023.</p><p>The approval from Japan was based on data from a phase 2 clinical study researching Ibtrozi in patients globally, including Japan, the company said.</p><p>The company said that when the reimbursement price in Japan is set, which is expected in Q4, it will receive a $25 million milestone payment to advance its pipeline and portfolio.</p><p><a href=\"https://laohu8.com/S/NUVB.WS\">Nuvation Bio</a> added that Japan's Ministry of Health, Labour and Welfare has also approved AmoyDx PLC Panel as a companion diagnostic to identify patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who may benefit from treatment with Ibtrozi.</p><p>Shares of the company were up 2.1% in recent Friday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuvation Bio's Ibtrozi Gets Japan Approval for Advanced ROS1-positive Non-Small Cell Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuvation Bio's Ibtrozi Gets Japan Approval for Advanced ROS1-positive Non-Small Cell Lung Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-19 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a> (NUVB) said Friday that Japan's Ministry of Health, Labour and Welfare has approved its Ibtrozi therapy to treat adult patients with advanced ROS1-positive non-small cell lung cancer.</p><p>The company said that <a href=\"https://laohu8.com/S/NPKYF\">Nippon Kayaku</a> will market Ibtrozi in Japan as part of a previously signed agreement in 2023.</p><p>The approval from Japan was based on data from a phase 2 clinical study researching Ibtrozi in patients globally, including Japan, the company said.</p><p>The company said that when the reimbursement price in Japan is set, which is expected in Q4, it will receive a $25 million milestone payment to advance its pipeline and portfolio.</p><p><a href=\"https://laohu8.com/S/NUVB.WS\">Nuvation Bio</a> added that Japan's Ministry of Health, Labour and Welfare has also approved AmoyDx PLC Panel as a companion diagnostic to identify patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who may benefit from treatment with Ibtrozi.</p><p>Shares of the company were up 2.1% in recent Friday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NUVB","symbol_name":"Nuvation Bio, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568683442","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568683442","pubTimestamp":1758283319,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Nuvation Bio  said Friday that Japan's Ministry of Health, Labour and Welfare has approved its Ibtrozi therapy to treat adult patients with advanced ROS1-positive non-small cell lung cancer.The company said that Nippon Kayaku will market Ibtrozi in Japan as part of a previously signed agreement in 2023.The approval from Japan was based on data from a phase 2 clinical study researching Ibtrozi in patients globally, including Japan, the company said.The company said that when the reimbursement price in Japan is set, which is expected in Q4, it will receive a $25 million milestone payment to advance its pipeline and portfolio.Nuvation Bio added that Japan's Ministry of Health, Labour and Welfare has also approved AmoyDx PLC Panel as a companion diagnostic to identify patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who may benefit from treatment with Ibtrozi.Shares of the company were up 2.1% in recent Friday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NUVB":"Nuvation Bio, Inc.","BK4007":"制药"},"translate_title":"Nuvation Bio的Ibtrozi获得日本批准用于晚期ROS1阳性非小细胞肺癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NUVB":1},"content_text":"Nuvation Bio (NUVB) said Friday that Japan's Ministry of Health, Labour and Welfare has approved its Ibtrozi therapy to treat adult patients with advanced ROS1-positive non-small cell lung cancer.The company said that Nippon Kayaku will market Ibtrozi in Japan as part of a previously signed agreement in 2023.The approval from Japan was based on data from a phase 2 clinical study researching Ibtrozi in patients globally, including Japan, the company said.The company said that when the reimbursement price in Japan is set, which is expected in Q4, it will receive a $25 million milestone payment to advance its pipeline and portfolio.Nuvation Bio added that Japan's Ministry of Health, Labour and Welfare has also approved AmoyDx PLC Panel as a companion diagnostic to identify patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who may benefit from treatment with Ibtrozi.Shares of the company were up 2.1% in recent Friday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}